News that AstraZeneca (LSE: AZN) was losing the experienced head of one its focus areas caused a slight share price wobble on Monday – but the company is confident that his shoes will be ably filled.
The Anglo-Swedish pharma major is losing Mondher Mahjoubi, its head of oncology, at the end of the month as he becomes chief executive of promising French biotech Innate Pharma (Euronext Paris: IPH), which is actually a partner of AstraZeneca in immuno-oncology.
A major reason for Dr Mahjoubi’s move is that it will enable him to be closer to his family in France, AstraZeneca has underlined. In a statement sent via email, the company also showed confidence in his replacement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze